AOD-9604 + CJC-1295 + Ipamorelin Blend

Key points

• The blend combines AOD-9604, a growth hormone fragment marketed for fat loss, with CJC-1295 and ipamorelin.
• CJC-1295 and ipamorelin are growth hormone peptides that prompt a pulse of growth hormone.
• None of the components is licensed in the UK, and selling them together does not change that.
• The components are prohibited in sport.

Quick facts

What it is

Blend of AOD-9604, CJC-1295 and ipamorelin

Marketed for

Fat loss and growth hormone support

UK status

Not a licensed medicine; sold for research use

In sport

Components on the WADA Prohibited List

How it works

The two growth hormone peptides aim to raise the body's own growth hormone, while AOD-9604 is marketed for fat breakdown. Each is covered in its own entry, where the limited evidence is set out.

What the evidence shows

There is no evidence for this blend as a specific product. The components have limited human evidence individually, and there are no trials of this combination.

What it does not settle

• There are no trials of this blend as sold.
• The exact contents and ratios of a given vial are uncertain.
• Long term safety of the combination is unknown.

Side effects

Less common but serious

• The risks are those of the individual components, with the added uncertainty of what a blended product contains.
• Because there is no licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

This blend has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use.

Common questions